Want to see AU:TRI full AI Analyst Report?
TrivarX Limited (TRI) AI Stock Analysis
TrivarX Limited
(ASX:TRI)
The overall score is at the minimum of the range, reflecting a highly speculative and high-risk profile. The company has no revenue, accelerating losses, and persistent cash burn, which are the most significant detractors. The stock's technical trend is firmly bearish, and the negative P/E provides no valuation support. The only relative strength is a clean balance sheet with minimal debt, but this is insufficient to offset the severe operational and market weaknesses.
TrivarX Limited (TRI) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 3.35M
- Dividend Yield
- ―
- Average Volume (3M)
- 705.07K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 2.35
- Revenue Growth
- ―
- EPS Growth
- -336.84%
- Country
- Australia
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
TrivarX Limited Business Overview & Revenue Model
Company Description
Operating as a health technology enterprise, TrivarX Limited specializes in crafting artificial intelligence-driven, scientifically validated instruments designed for the assessment and identification of behavioral health disorders. Its market presen...
TrivarX Limited Financial Statement Overview
Summary
The company is pre-revenue with zero sales and deeply negative, deteriorating profitability. Net losses widened to -$8.8M and operating cash burn remains high. The only mitigating factor is a strong, low-debt balance sheet, but the income and cash flow statements are critically weak.
Income Statement
1Very NegativeBalance Sheet
65PositiveCash Flow
10Very Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -6.47M | -6.47M | -52.47K | -93.13K |
| EBITDA | -1.95M | -1.95M | -1.89M | -1.13M |
| Net Income | -8.76M | -8.76M | -943.23K | -1.24M |
Balance Sheet | ||||
| Total Assets | 16.53M | 16.53M | 13.48M | 10.81M |
| Cash, Cash Equivalents and Short-Term Investments | 2.44M | 2.44M | 1.25M | 848.10K |
| Total Debt | 128.14K | 128.14K | 169.03K | 15.90K |
| Total Liabilities | 565.64K | 565.64K | 831.22K | 1.18M |
| Stockholders Equity | 15.97M | 15.97M | 12.65M | 9.88M |
Cash Flow | ||||
| Free Cash Flow | -542.85K | 0 | -189.74K | -3.70M |
| Operating Cash Flow | -1.51M | -1.51M | -189.74K | -1.48M |
| Investing Cash Flow | -1.17M | -1.17M | -2.09M | -2.85M |
| Financing Cash Flow | 3.87M | 3.87M | 2.68M | 4.32M |
TrivarX Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRI, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 28.09 is Positive, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TRI.
TrivarX Limited Peers Comparison
Overall Rating
AU:RHT69Neutral
AU:ICR45Neutral
AU:AHE42Neutral- AU:TRI37Underperform
AU:PKY37Underperform
AU:PCK27Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:RHT | 69Neutral | AUD 35.31M | 23.13 | 13.72% | ― | 42.25% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:ICR | 45Neutral | AUD 14.31M | -5.88 | -416.53% | ― | 113.42% | 29.17% |
| AU:AHE | 42Neutral | AUD 8.93M | -0.45 | -614.15% | ― | -46.09% | 70.70% |
| AU:TRI | 37Underperform | AUD 10.38M | -0.01 | -44.34% | ― | ― | -336.84% |
| AU:PKY | 37Underperform | AUD 21.63M | -1.93 | -18.10% | ― | ― | ― |
| AU:PCK | 27Underperform | AUD 16.32M | -1.80 | -1688.04% | ― | 11.45% | 0.69% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:TRI | Trivarx Limited | 0.01 | -0.01 | -52.38% | |
| AU:RHT | Resonance Health Ltd | 0.07 | 0.02 | 51.02% | |
| AU:PKY | Opyl Ltd. | 0.02 | 0.00 | 0.00% | |
| AU:AHE | MedAdvisor Limited | 0.01 | -0.01 | -46.15% | |
| AU:ICR | InteliCare Holdings Limited | 0.02 | 0.00 | 11.11% | |
| AU:PCK | PainChek Ltd | 0.08 | -0.37 | -82.67% |
TrivarX Limited Corporate Events
TrivarX advances Stabl-Im platform toward clinical feasibility study
TrivarX has reported steady progress in the clinical and technical development of its Stabl-Im platform, with pre-clinical study designs completed and animal studies underway to support a planned clinical feasibility trial. The company has also final...
TrivarX Sets AGM Date and Director Nomination Deadline
TrivarX Limited has scheduled its Annual General Meeting for 19 November 2026, with further details to be provided to shareholders in forthcoming AGM materials. The company has also set 30 September 2026 as the deadline for written director nominatio...
TrivarX posts steep annual loss as revenue collapses but per-share asset backing rises
TrivarX Limited has reported a sharp deterioration in its financial performance for the year ended 30 June 2026, with revenue from ordinary activities plunging to $14,566 from $1.13 million a year earlier. The company’s net loss attributable to...
TrivarX refocuses on Stabl-Im as new CEO drives clinical push
TrivarX has sharpened its development strategy under new chief executive Dr Danielle Meyrick, prioritising disciplined clinical execution and capital allocation around its Stabl-Im imaging platform while limiting near-term spend on mental health tech...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 25, 2026